Vascular Endothelial Growth Factor Inhibitor

This page covers all Vascular Endothelial Growth Factor Inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Vascular endothelial growth factor A, VEGFA.

Targets

Vascular endothelial growth factor A · VEGFA

Marketed (6)

• Vegf Trap · Regeneron · Oncology · 9800
• Avastin · Roche · Oncology · 2100
  Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors.
• PAVBLU · AMGEN INC · Other
• CIMERLI · SANDOZ INC · Other
• VEGZELMA · CELLTRION · Other
• JOBEVNE · BIOCON BIOLOGICS INC · Other

Phase 2 pipeline (1)

• Anti-EGFR or Bevacizumab · Grupo Espanol Multidisciplinario del Cancer Digestivo · Oncology
  Inhibits vascular endothelial growth factor A (VEGFA)

Patent intelligence

• vascular endothelial growth factor inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates